Global Microbiome Therapeutics Market Projected to Reach USD 838.2 Million by 2026

17-Jun-2020 | Facts and Factors

Findings from Facts and Factors report “Microbiome Therapeutics Market By Product (Prebiotics, Probiotics, Synbiotics), By Application (C. difficile, Crohn’s Disease, Inflammatory Bowel Disease [IBD], Diabetes) and By Distribution Channel (Drug stores, Super And Hypermarkets, Hospital Pharmacies, And E-Commerce Stores): Global Industry Outlook, Market Size, Business Intelligence, Consumer Preferences, Statistical Surveys, Comprehensive Analysis, Historical Developments, Current Trends, and Forecasts, 2020–2026” states that the global microbiome therapeutics market in 2019 was approximately USD 34.1 Million. The market is expected to grow above a CAGR of 58 % and is anticipated to reach over USD 838.2 Million by 2026.

The microbiome is a genetic material of all the microbes that resides within the body. The microbes contain 200 times the number of genes as compared to human genome. The microbiome consists of thousands of different bacterial species mainly in the mouth, vagina and the mouth. The gut microbiome is an important element that assist in controlling digestion and improving immunity system. The balance of microbes is very important as it may result in weight gain, high cholesterol, high blood sugar and other disorders.

Browse the full “Microbiome Therapeutics Market By Product (Prebiotics, Probiotics, Synbiotics), By Application (C. difficile, Crohn’s Disease, Inflammatory Bowel Disease [IBD], Diabetes) and By Distribution Channel (Drug stores, Super And Hypermarkets, Hospital Pharmacies, And E-Commerce Stores): Global Industry Outlook, Market Size, Business Intelligence, Consumer Preferences, Statistical Surveys, Comprehensive Analysis, Historical Developments, Current Trends, and Forecasts, 2020–2026" https://www.fnfresearch.com/microbiome-therapeutics-market-by-product-prebiotics-probiotics-synbiotics-1208

The extensive and prolonged consumption of antibiotics, non healthy food consumption, and aging are major factors responsible for redution in vital microorganisms in the body. This decreased level of vital microorganisms has ld to growth of harmful infectious diseases and organisms like clostridium difficile and ulcerative colitis. The number of individuals affected by C. difficile has been growing year on year. The people having antibiotic treatment are more susceptible to C. difficile. The side effect caused by the existing dosage of medicines during various treatment is expected to play important role in the growth of global microbiome therapeutics market.

Additionally, increasing investment in research and development as well as the rising venture capitalist investment towards microbiome therapeutics market are further propelling the growth of global microbiome therapeutics market.

The C. difficile segment is expected to continue the dominance over the studied period. The higher share during the forecast period is owing to early introduction in the market and successive multiple types. The Crohn’s disease is expected to grow at fastest rate during the forecast period. The major development and continuous research in the gastrointestinal disorder treatment including the Crohn’s disease, inflammatory bowel disease, ulcerative colitis is expected to lead the market growth in these segments.

The North America region is estimated to hold maximum share in the base year. The North America region is expected to continue dominance over the forecast period. The region has wealthy yet health conscious population as well as presence of major players. Additionally, the number of research facilities involved in development of novel therapeutics in the region are also higher. The Asia Pacific region is expected to witness significant growth in foreseeable future. The major factors responsible for the expected growth are the rising economic conditions and the expanding pharmaceuticals sector. The Europe market is estimated to remain second largest contributor to the global market revenue.

Report Scope

Some of the leading players in the global market include

Pfizer Inc., Yakult, AbbVie Inc., Ganeden, AB-Biotics, Johnson and Johnson, Vedanta Biosciences, Bayer, Dannon, Sigma-Tau Pharmaceuticals, and Others.

This report segments the global microbiome therapeutics market as follows:

By Product type Segmentation Analysis

• Prebiotics
• Probiotics
• Synbiotics

By Distribution Channel Segmentation Analysis

• Drug Stores
• Super and Hypermarkets
• Hospital Pharmacies
• Retail Pharmacies
• E-Commerce Stores

By Application Segmentation Analysis

• C. Difficile
• Crohn’s Disease
• Inflammatory Bowel Disease [IBD]
• Diabetes

By Regional Segmentation Analysis

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

About Us:

Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.

Contact Us:
Facts & Factors
A 2108, Sargam,
Nanded City,
Sinhagad Road,
Pune 411041, India
USA: +1-347-989-3985
Email: [email protected]
Web: https://www.fnfresearch.com